IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

Find insight on Novo Nordisk Foundation, ResMed, Johnson & Johnson, and more in the latest Market Talks covering Health Care.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...